01.26.23
Essity’s net sales in 2022 increased 28.2% to SEK 156.2 billion ($15.3 billion). Sales growth, including organic sales growth and acquisitions, amounted to 17.7%. Organic sales growth, which excludes exchange rate effects, acquisitions and divestments, amounted to 15.7%, of which volume accounted for 1.7% and price/mix for 14%. Organic sales growth in mature markets amounted to 17.5% and in emerging markets to 12.8%. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 10.6%. Acquisitions increased net sales by 2%. Divestments reduced net sales by 0.1%.
In Health & Medical, full year 2022 net sales increased 16.4% to SEK 25.2 billion ($2.5 billion). Sales growth, including organic sales growth and acquisitions, amounted to 9.6%. Organic sales growth amounted to 7.3%, of which volume accounted for 2.5% and price/mix for 4.8%. The organic sales growth amounted to 5.5% in mature markets. In emerging markets, which accounted for 20% of net sales, organic sales growth was 14.5%. Exchange rate effects increased net sales by 7.3%. Acquisitions increased net sales by 2.3%. Divestments reduced net sales by 0.5%. For Incontinence Products Health Care, organic sales growth amounted to 7.1% due to higher volumes and higher prices. In Medical Solutions, organic sales growth amounted to 7.6% as a result of higher volumes and higher prices. Sales growth was high in Wound Care and Orthopedics.
In the Consumer Goods segment, full year 2022 net sales increased 28.1% to SEK 94.8 billion ($9.3 billion). Sales growth, including organic sales growth and acquisitions, amounted to 17.5%. Organic sales growth amounted to 15.7%, of which volume accounted for 0.1% and price/mix for 15.6%. Organic sales growth amounted to 18.7% in mature markets. In emerging markets, which accounted for 49% of net sales, organic sales growth was 12.6%. Exchange rate effects increased net sales by 10.6%. Acquisitions increased net sales by 1.8%. For Incontinence Products Retail, organic sales growth amounted to 10.8%, in Feminine Care to 15.7% and in Baby Care to 1%. In Consumer Tissue, organic sales growth amounted to 19.1% and for the Consumer Tissue Private Label Europe division to 35.8%. Prices were higher in all categories. Baby Care was negatively impacted by the discontinuation of the baby diaper business in Latin America.
In the fourth quarter of 2022, net sales increased 28.1% to SEK 43.8 billion ($4.7 billion). Sales growth, including organic sales growth and acquisitions, amounted to 16%. Organic sales growth, which excludes exchange rate effects, acquisitions and divestments, amounted to 14.3%, of which volume accounted for -4.3% and price/mix for 18.6%. Organic sales growth in mature markets amounted to 17.9% and in emerging markets to 8.9%. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 12.2%. Acquisitions increased net sales by 1.7%. Divestments reduced net sales by 0.1%.
In Health & Medical, Q4 net sales increased 14.9% to SEK 6.7 billion ($655 million). Sales growth, including organic sales growth and acquisitions, amounted to 6.3%. Organic sales growth amounted to 4.6%, of which volume accounted for -2.0% and price/mix for 6.6%. The organic sales growth amounted to 4.3% in mature markets. In emerging markets, which accounted for 20% of net sales, organic sales growth was 5.6%. Exchange rate effects increased net sales by 9.0%. Acquisitions increased net sales by 1.7%. Divestments reduced net sales by 0.4%. For Incontinence Products Health Care organic sales growth amounted to 3.8% due to higher prices. In Medical Solutions, organic sales growth amounted to 5.7% mainly as a result of higher prices. Sales growth was high in Wound Care and Orthopedics.
In the Consumer Goods segment, Q4 net sales increased 29.8% to SEK 27.1 billion ($2.7 billion). Sales growth, including organic sales growth and acquisitions, amounted to 17.8%. Organic sales growth amounted to 15.7%, of which volume accounted for -4.6% and price/mix for 20.3%. Organic sales growth amounted to 21.4% in mature markets. In emerging markets, which accounted for 49% of net sales, organic sales growth was 10.1%. Exchange rate effects increased net sales by 12%. Acquisitions increased net sales by 2.1%. For Incontinence Products Retail, organic sales growth amounted to 10.3%, in Feminine Care to 10.7% and in Baby Care to -6.5%. In Consumer Tissue, organic sales growth amounted to 20.9% and for the Consumer Tissue Private Label Europe division to 48.7%. Prices were higher in all categories. Volumes in Baby Care were negatively impacted by the discontinuation of the baby diaper business in Latin America.
In Health & Medical, full year 2022 net sales increased 16.4% to SEK 25.2 billion ($2.5 billion). Sales growth, including organic sales growth and acquisitions, amounted to 9.6%. Organic sales growth amounted to 7.3%, of which volume accounted for 2.5% and price/mix for 4.8%. The organic sales growth amounted to 5.5% in mature markets. In emerging markets, which accounted for 20% of net sales, organic sales growth was 14.5%. Exchange rate effects increased net sales by 7.3%. Acquisitions increased net sales by 2.3%. Divestments reduced net sales by 0.5%. For Incontinence Products Health Care, organic sales growth amounted to 7.1% due to higher volumes and higher prices. In Medical Solutions, organic sales growth amounted to 7.6% as a result of higher volumes and higher prices. Sales growth was high in Wound Care and Orthopedics.
In the Consumer Goods segment, full year 2022 net sales increased 28.1% to SEK 94.8 billion ($9.3 billion). Sales growth, including organic sales growth and acquisitions, amounted to 17.5%. Organic sales growth amounted to 15.7%, of which volume accounted for 0.1% and price/mix for 15.6%. Organic sales growth amounted to 18.7% in mature markets. In emerging markets, which accounted for 49% of net sales, organic sales growth was 12.6%. Exchange rate effects increased net sales by 10.6%. Acquisitions increased net sales by 1.8%. For Incontinence Products Retail, organic sales growth amounted to 10.8%, in Feminine Care to 15.7% and in Baby Care to 1%. In Consumer Tissue, organic sales growth amounted to 19.1% and for the Consumer Tissue Private Label Europe division to 35.8%. Prices were higher in all categories. Baby Care was negatively impacted by the discontinuation of the baby diaper business in Latin America.
In the fourth quarter of 2022, net sales increased 28.1% to SEK 43.8 billion ($4.7 billion). Sales growth, including organic sales growth and acquisitions, amounted to 16%. Organic sales growth, which excludes exchange rate effects, acquisitions and divestments, amounted to 14.3%, of which volume accounted for -4.3% and price/mix for 18.6%. Organic sales growth in mature markets amounted to 17.9% and in emerging markets to 8.9%. Emerging markets accounted for 37% of net sales. Exchange rate effects increased net sales by 12.2%. Acquisitions increased net sales by 1.7%. Divestments reduced net sales by 0.1%.
In Health & Medical, Q4 net sales increased 14.9% to SEK 6.7 billion ($655 million). Sales growth, including organic sales growth and acquisitions, amounted to 6.3%. Organic sales growth amounted to 4.6%, of which volume accounted for -2.0% and price/mix for 6.6%. The organic sales growth amounted to 4.3% in mature markets. In emerging markets, which accounted for 20% of net sales, organic sales growth was 5.6%. Exchange rate effects increased net sales by 9.0%. Acquisitions increased net sales by 1.7%. Divestments reduced net sales by 0.4%. For Incontinence Products Health Care organic sales growth amounted to 3.8% due to higher prices. In Medical Solutions, organic sales growth amounted to 5.7% mainly as a result of higher prices. Sales growth was high in Wound Care and Orthopedics.
In the Consumer Goods segment, Q4 net sales increased 29.8% to SEK 27.1 billion ($2.7 billion). Sales growth, including organic sales growth and acquisitions, amounted to 17.8%. Organic sales growth amounted to 15.7%, of which volume accounted for -4.6% and price/mix for 20.3%. Organic sales growth amounted to 21.4% in mature markets. In emerging markets, which accounted for 49% of net sales, organic sales growth was 10.1%. Exchange rate effects increased net sales by 12%. Acquisitions increased net sales by 2.1%. For Incontinence Products Retail, organic sales growth amounted to 10.3%, in Feminine Care to 10.7% and in Baby Care to -6.5%. In Consumer Tissue, organic sales growth amounted to 20.9% and for the Consumer Tissue Private Label Europe division to 48.7%. Prices were higher in all categories. Volumes in Baby Care were negatively impacted by the discontinuation of the baby diaper business in Latin America.